Key result
ISCHEMIA-PREDICT score stratifies mortality risk in chronic coronary syndrome to guide tailored clinical decisions.
Why the study?
Does the ISCHEMIA-PREDICT risk score accurately predict all-cause mortality in patients with chronic coronary syndrome?
Does the ISCHEMIA-PREDICT risk score accurately predict all-cause mortality in patients with chronic coronary syndrome?
The ISCHEMIA-PREDICT risk score uses routinely available clinical data to accurately predict all-cause mortality in patients with chronic coronary syndrome, aiding in risk-guided decision-making for intensified medical or invasive therapy.
Answers are grounded in this paper and cite their sources.
Supports tailored therapy intensification in chronic coronary syndrome; extends validation of a routine-data risk model to contemporary real-world cohorts.
What we did and found: Using the randomized ISCHEMIA trial (5179 patients), we built a risk score from routinely available data-glomerular filtration rate, ST-segment depression and exercise duration on a stress test, systolic blood pressure, multivessel coronary disease, and initial treatment strategy (invasive vs. conservative). The score clearly separated lower- from higher-risk patients and showed strong discrimination. Its performance for all-cause death was confirmed in an independent, contemporary multicentre registry of over 23 000 patients with long-term follow-up. Why it matters for patients and clinicians: Because it relies on familiar information collected in everyday practice, ISCHEMIA-PREDICT can help clinicians quickly gauge mortality risk in chronic coronary syndrome patients and tailor care accordingly-supporting intensified medical therapy and consideration of invasive management in those at highest risk. A web calculator enables point-of-care use and risk-guided decision-making.
No takes yet. Share an insight, caveat, or question.
Navarese et al. (2026) studied this question. The ISCHEMIA-PREDICT score stratifies mortality risk in chronic coronary syndrome, validated in over 23,000 patients, aiding in tailored clinical decision-making.
Synapse has enriched 10 related papers. Consider them for comparative context: